Clinical Ink is merging with CentrosHealth to create a world-class clinical trial technology platform that can be used to conduct truly “paperless” clinical trials with purpose-built solutions for pharma companies, research sites, and patients. The company [Clinical Ink] also announced that MPM Capital and F2 Ventures joined FCA Venture Partners and other existing investors to provide additional growth capital for aggressive expansion of operational capabilities and further development of the clinical trial platform. Moreover, it has entered into a strategic partnership with Novartis Pharmaceuticals, as part of their Trials of the Future initiative, to help drive industry-wide adoption of fully electronic clinical trials.

“The combination of Clinical Ink and CentrosHealth backed by the deep expertise, relationships, and financial resources of MPM Capital creates a powerful opportunity to transform the clinical development business model,” said Ed Seguine, CEO of Clinical Ink. “This multi-part transaction underscores the tremendous progress we’ve made and the future potential for our combined businesses to deliver innovative technology solutions that eliminate the root causes of clinical trial inefficiency.”

As a result of this transaction representatives from MPM Capital and F2 Ventures will join the existing board of directors of Clinical Ink.Clinical Ink makes eSource solutions for clinical trials, while CentrosHealth provides configurable mobile apps for clinical trial patient engagement and electronic patient reported outcomes (ePRO).

By using CentrosHealth and SureSource, the eSource platform can receive data both from the site and the patient, in real-time and can dramatically reduce the cost, time, and complexity of the clinical trial process. The Clinical Ink approach to eSource and mobile data capture has been endorsed by both FDA and EMA and is an integral component of novel “risk-based monitoring” approaches to clinical research oversight.

As a result of this transaction representatives from MPM Capital and F2 Ventures will join the existing board of directors of Clinical Ink.

UPDATE: According to a report at MobiHealthNews (and an SEC filing), at least $9.8 million was spent on the merger.